GlassScriptPhysician profile
Theodore S Hausler
NPI 1629413075
$14,680.62
in general payments reported to CMS, 2019-2025
65 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $1,486 · 2021: $3,050 · 2022: $2,358 · 2023: $2,380 · 2024: $2,359 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,101 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,100.70 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,528.01 | 2019-2025 | |
| Novo Nordisk INC | $1,252.79 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,239.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,013.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $697.94 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $689.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $668.35 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $538.84 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $523.12 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $479.21 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $402.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $361.42 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $334.35 | 2022-2025 | |
| Exact Sciences Corporation | $300.84 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $284.07 | 2020-2021 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Hausler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.